YOLO - AdvisorShares Pure Cannabis ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
+0.49 (+2.60%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close18.84
Bid0.00 x 900
Ask0.00 x 800
Day's Range19.14 - 19.42
52 Week Range18.76 - 26.50
Avg. Volume55,341
Net Assets57.87M
PE Ratio (TTM)N/A
YTD ReturnN/A
Beta (3Y Monthly)N/A
Expense Ratio (net)0.74%
Inception Date2019-04-17
Trade prices are not sourced from all markets
  • Benzinga

    A Couple Data Points On The Main Drivers Of Cannabis Stock Investing

    A recent user survey conducted by Investing.com revealed that state legislation regarding marijuana legalization is driving investor interest in pot stocks. Looking into 8 million users across the U.S., they found that investors in states that had legalized marijuana showed the a much greater interest in investing in the substance, with Maine, Massachusetts, Michigan, Alaska and California ranking as the top five states for investor interest. Investing.com's partner on the survey, SEMrush also found a drastic increase in Google searches for pot socks in each of the aforementioned states following legalization, in excess of 100% in most cases.

  • Benzinga

    Global Alliance For Cannabis Commerce Launches In Los Angeles

    Article originally posted on LA Weekly, provided to Benzinga Cannabis by the author. A new national advocacy organization has launched in Los Angeles to advocate and educate lawmakers on the path towards federal cannabis legalization. Mr. Jason Beck, a longtime Angeleno who was born with cerebral palsy and an early medical cannabis patient, spearheaded the creation of the new organization.  The Global Alliance for Cannabis Commerce (GACC) will focus on legislation including, cultivation, manufacture, distribution, public safety, and taxation of medical and adult-use cannabis.

  • Benzinga

    Big Opportunities: Michigan Cannabis Market 'Could Easily Eclipse $2B'

    Since Michigan voters approved and created the Michigan Regulation and Taxation of Marijuana Act (MRTMA) in late 2018, which legalized recreational usage of marijuana within certain parameters, the state has become a hub of cannabis startups and investors. Both agree Michigan represents an enormous opportunity for companies and investors.

  • Cannabis Stocks’ Volatility Spike Tied to ETF’s Mega Trades

    Cannabis Stocks’ Volatility Spike Tied to ETF’s Mega Trades

    The speculative nature of the cannabis industry has led to some wild swings in pot stocks, but an ETF's big trades are also adding to the volatility.

  • Benzinga

    Is Oregon Set To Legalize Magic Mushrooms?

    Oregon is one step closer to voting in November 2020 to legalize medicinal psilocybin mushrooms for adults in the state. While current laws prohibit the use and possession of psilocybin, a hallucinogenic compound from "magic mushrooms," activists in the state are championing the Oregon Psilocybin Services Act. Under the proposed measure, the Oregon Health Authority (OHA) would establish a regulatory program allowing for the production, processing, delivery, possession and administration of psilocybin.

  • Benzinga

    7 Cannabis Business Tips From Leading Marijuana Retailers

    By the end of 2019, retail sales are expected to top $12 billion - an increase of 35%, according to Marijuana Business. It’s one thing to offer the best bud, but in today’s retail landscape where new brands and product categories are emerging, it’s important to stay current with shifting trends and tastes of consumers. As the cannabis industry’s wholesale marketplace, LeafLink works with thousands of retailers to simplify their purchasing processes.

  • Benzinga

    The Complicated Business Of Advertising And Marketing In Cannabis

    By Aaron Silverman, President of MediaJel . New companies tend to cultivate similarly. Build a winning team and culture. Plan and establish your vision of success – but maintain flexibility. Structure ...

  • Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF

    Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF

    CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.

  • ETFs in Focus as Consolidation Drives Marijuana Industry

    ETFs in Focus as Consolidation Drives Marijuana Industry

    Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.

  • Benzinga

    Want to Get a Medical Marijuana Card? Here's What You Need to Know

    While cannabis remains illegal under federal law, state-approved medical marijuana programs continue to sprout like weeds across the United States – and in other parts of the world, too. The key that allows you to reap the benefits of the cannabis plant is a state-specific identification card called the medical marijuana card (also known as a cannabis card or weed card). As of July 2019, the use of cannabis for medicinal purposes has been legalized in 33 states, along with Washington, D.C. As the first state to legalize medical marijuana, California drew the initial blueprint with the 1996 passage of the Medical Use of Marijuana Initiative.

  • Benzinga

    Has The Moment For Cannabis Banking Reform Finally Arrived?

    The multi-billion-dollar cannabis industry in the U.S. is largely restricted to cash-only transactions. Will Congress or technology companies be the first to provide a solution for this growing industry?

  • Benzinga

    Why You Should Attend The Cannabis Capital Conference In Detroit

    After three incredibly successful versions of the Cannabis Capital Conference, the Benzinga events team is bringing the next iteration to our hometown of Detroit. The Cannabis Capital Conference takes place Aug. 15 at the Westin Book Cadillac in downtown Detroit. Who Comes To The Conference? The most important part of Benzinga events remains the strong focus on connecting well-vetted companies with a high tier of institutional and accredited investors.

  • Benzinga

    How Medical Cannabis Eases HIV Symptoms, Reduces Disease Progression

    Human Immunodeficiency Virus (HIV) may no longer be a death sentence, but it is a life sentence for those who are coping with the chronic symptoms of the virus. There are dozens of HIV/AIDS drugs on the market which reduce viral loads in the body and ease certain symptoms, but also cause unpleasant side effects such as headache and nausea. Well-known as an appetite stimulant, cannabis has been used to manage the anorexia and wasting disease symptoms of HIV/AIDS, but the plant might be able to go even further beyond this basic treatment.

  • Benzinga

    Charts: CBD Search Interest Is More Popular Than Beyonce, Kim Kardashian And Veganism

    CannabisMD recently compared relative search volumes for CBD and Beyonce, Kim Kardashian, kale and veganism. The findings were a bit surprising.  “Looking at 2018 trends, CBD grew by over 260 percent in ...

  • Benzinga

    Argentina To Host Its First Big Cannabis Business Expo: 'Cannabis Improves People's Quality Of Life'

    Argentina will hold its first big cannabis conference, Expo Cannabis, Oct. 4 -6 at the La Rural event hall in Buenos Aires. The South American country is far behind its tiny neighbour Uruguay in terms of cannabis legalization, but things could soon change. Argentina’s cannabis industry is literally seeing its first sprouts.

  • Benzinga

    What The Public Needs To Know: Your Brain Is Already On CBD

    Why is the hemp plant so good for us? Thankfully, doctors can run tests for these deficiencies and work to find hormone replacement therapy or medicine and therapy that can help with the myriad issues caused by an upset to the balance our bodies want and need.

  • Benzinga

    Cory Booker Slams Joe Biden's Marijuana Reform Plan Ahead Of Detroit Dem Debate

    It’s not even 2020, but the 2020 Election is already turning personal and combative between presidential candidates for the Democratic nomination. This week saw Sen. Cory Booker aim directly at former Vice President Joe Biden, who released his extensive plan for criminal justice reform, which included Biden’s proposal to reclassify marijuana as a Schedule II drug. Among Democrat presidential candidates, Biden is the least progressive on marijuana reform with his views barely evolving since 1989.

  • Benzinga

    'Billion Dollar Dimebag' Author Jackson Tilley On Sobriety, LGBTQ+ Acceptance In The Cannabis Industry

    Jackson Tilley’s "Billion Dollar Dimebag," which hits bookshelves Sept. 17, is an exploration of the intersection of business, diversity and THC. Before "Billion Dollar Dimebag," Tilley's experiences in the cannabis sphere were almost mundane. After college, he began working at Organa Brands and later at SLANG Worldwide.

  • Benzinga

    Podcast: Cannabis Finance And International Opportunities With Benzinga's Javier Hasse

    The cannabis industry is evolving at a faster pace than ever! Host Wayne Schwind, Founder and Owner of Periodic Edibles discusses those items and more with Benzinga Cannabis' Managing Director Javier Hasse, book author with Entrepreneur Media, and reporter published on Forbes, Entrepreneur, High Times, and more. Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!

  • As Oversupply Skyrockets, Canopy Growth Stock Has Further to Fall

    As Oversupply Skyrockets, Canopy Growth Stock Has Further to Fall

    Another week, same dismal trading in marijuana stocks. Things are looking even worse for Canopy Growth (NYSE:CGC). Canopy Growth stock is down nearly 40% since the end of April and is threatening to make new 2019 lows. As of this writing, it's already down 5% this week. And they're not alone.Source: Shutterstock Traders opened Monday's trading by dumping shares in the beleaguered marijuana sector. The Alternative Harvest ETF (NYSEARCA:MJ) dropped more than 2%, hitting its lowest level since the second week of January. It's down nearly 30% since its springtime high.What's going on? Arguably, investor sentiment outstripped consumer demand for marijuana. While investors have rushed to get money into the marijuana sector in 2019, actual consumer demand for cannabis has fallen far short of production levels. Let's take a look at both aspects of this imbalance.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy With Over 20% Upside From Current Levels Investor Interest and Canopy Growth StockSpeculators have gotten increasingly excited about the marijuana sector in recent years. Canada's full legalization of the drug last fall really changed a lot of perspectives. Many folks started viewing it as a legitimate industry and rushed to get in on the ground floor. Also, it's no secret that alcohol and tobacco stocks have been two of the greatest performers over the years. Investors have made fortunes buying and holding vice shares. So why not marijuana?This year, investor demand has played out through the rise of ETFs. Our Matt McCall noted the surge in new marijuana ETFs this year:YOLO is actually a ticker symbol for a recent marijuana-related exchange-traded fund (ETF) called the AdvisorShares Pure Cannabis ETF (NYSEARCA:YOLO), which debuted in April. As legalization spreads and the industry grows, cannabis ETFs are in the midst of their own marijuana craze. In just the last couple of weeks, three new funds have started trading or announced that they are about to: The Cannabis ETF (NYSEARCA:THCX), Amplify Seymour Cannabis ETF (NYSEARCA:CNBS), and Cambria Marijuana ETF (BATS:TOKE).I must say, YOLO and TOKE win the best symbols award … at least for now.I'd note that oftentimes when things get cute, sentiment is near its peak. When you start seeing products with goofy ticker symbols like TOKE and YOLO, it's generally a sign that people are a bit too excited. The YOLO ETF, for example, is off to a rough start, down from $25 to under $20 since its recent launch. Not Enough Consumer DemandCanada's health department has kept track of supply and demand data for the marijuana industry since legalization last fall. It publishes new data each month. The latest results, for May 2019, continue a most worrisome trend for the industry.Last October, when legalization became law, Canada had roughly 115,000 kilograms of completed and in-progress dried cannabis inventory. In May, this jumped to 264,000 kilograms. From April to May alone, inventory levels surged by around 40,000 kilograms.This is a disaster for Canadian marijuana producers because Canadian consumption is still under 10,000 kilograms a month. Thus, marijuana suppliers are producing roughly four times as much product as Canadians are actually buying. And there's no sign of this inventory glut slowing down.The supply of cannabis oil has similarly skyrocketed. It's up by 150% since legalization to 128,000 liters of inventory. Consumption, however, is up by roughly just 50%/month and remains under 10,000 liters per month. Thus, there are more than two years of dried cannabis inventory and one year of CBD oil inventory available at current supply and demand levels. And supply growth continues to outstrip demand increases, making the excess even worse. Canopy Keeps Growing, but Will Its Market?Canopy itself has become a massive player. It's on pace to have more than five million square feet of growing operations in Canada alone by the end of next year. And it may do much more overseas. In Colombia, for example, it has a license to cultivate up to 35 million square feet of cannabis. But who is going to consume this mountain of weed going forward?Canopy's growth at all costs strategy appears to be shaking key backers' confidence. For example, Constellation Brands (NYSE:STZ), which owns a massive chunk of Canopy, is getting nervous. Constellation helped force founder and CEO Bruce Linton out of Canopy.Rumors suggested that this was because Constellation was unhappy with Canopy's financial performance, though Constellation denied this and claimed it instead wanted a different CEO to lead the company's next phase of growth. In any case, the CGC stock price performance has surely not pleased Constellation's leaders in recent months. Canopy Growth Stock VerdictA recent survey found that 44% of British Columbian residents are within C$200 of ending up broke at the end of every month. Given that Vancouver is a major marijuana market, this could be an issue. And it's a worsening of recent trends as the economy has weakened amidst a slump in the housing market there.Perhaps people don't have enough money for discretionary purchases like marijuana. Or perhaps, as people say about alcohol, people will simply buy more because they are stressed out about the sour economy.In any case, if you own Canopy Growth stock, you really have to hope something changes, and soon. Otherwise, there's going to be a lot more stress ahead in the coming quarters. The company has committed to a massive growth program that is blowing through hundreds of millions of dollars.Yes, the company is still well-funded from its Constellation partner. But Canopy is burning through that cash quickly and the share price will keep sinking with it unless the outlook for the marijuana market improves.Based on the numbers in Canada, however, the situation is only getting worse. For now, Canopy Growth stock is likely to keep trending lower. If you want to buy Canopy Growth stock, wait, and you'll be able to get it cheaper.At the time of this writing, Ian Bezek held no position in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Small-Cap Stocks to Buy Before They Grow Up * 7 Stocks to Buy With Over 20% Upside From Current Levels * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post As Oversupply Skyrockets, Canopy Growth Stock Has Further to Fall appeared first on InvestorPlace.

  • Benzinga

    420 In 2020: Every Democratic Presidential Candidate's Cannabis Position

    Former Vice President Joe Biden does not support full legalization of cannabis, but rather decriminalization. Biden has been criticized for writing the 1994 crime bill dovetailed with a significant increase in incarceration rates across the country, including for marijuana possession. At the NAACP National Convention last week, Sen. Kamala Harris of California said she wants to legalize and decriminalize cannabis.

  • Another Marijuana ETF, Cambria Cannabis, Joins the Party

    Another Marijuana ETF, Cambria Cannabis, Joins the Party

    For investors who like exchange traded funds (ETFs) and marijuana stocks, these are wonderful days. Just in July, three new marijuana ETFs have come to market in the U.S., including two during the week of July 22.There are now five cannabis ETFs listed in New York after there was just one at the start of this year. But beyond that, an increasing number of these funds are actively managed. In fact, three of the four marijuana ETFs that have come to market in 2019 are actively managed, including both of the funds that launched last week.The most recent addition to the marijuana ETF fray is the Cambria Cannabis ETF (CBOE:TOKE). TOKE is certainly a candidate for "ticker of the year" among the crop of 2019 rookie cannabis ETFs.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 4 Stocks to Buy That Are Surging After Earnings TOKE "seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry," according to Cambria. "The Fund will target investing in approximately 20 to 50 of the top companies with exposure to the broad cannabis industry based on Cambria's determination as to their exposure to the industry," it added.TOKE debuted with 34 holdings, including familiar names such as Aurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:CGC). While it is accurate to say that many of the largest cannabis companies aren't really large-cap stocks or barely qualify for that designation, TOKE tilts toward "micro-, small-, and mid-capitalization stocks," according to the issuer. A Tradition of UpstartsAnother interesting element of the rising competition among cannabis ETFs is that all of the issuers in the space can be considered "upstarts." Indeed, smaller issuers can potentially launch successful marijuana ETFs because it is unlikely that more traditional firms, such as iShares, Vanguard or Schwab, will ever enter this space. For its part, Cambria fits the bill as an upstart ETF issuer and a successful one at that."The fund management industry is dominated by a handful of firms with massive sales and distribution, but we believe investors are looking for original, authentic investment solutions," said Cambria founder Meb Faber in a statement. "Our firm's growth to date is a testament to the trust of our over 30,000 investors who support us, our ideas, and our research. We've approached asset management a bit differently and we're excited to continue launching innovative solutions investors care about."Well-known Cambria ETFs include the Cambria Tail Risk ETF (CBOE:TAIL), Cambria Shareholder Yield ETF (CBOE:SYLD) and the Cambria Global Value ETF (CBOOE:GVAL), among others.As for TOKE, its lineup is somewhat concentrated, with its top ten holdings representing nearly half the fund's weight.Time will tell if active management works for marijuana ETFs, but actively managed marijuana ETFs got off to a bumpy start. The AdvisorShares Pure Cannabis ETF (NYSEARCA:YOLO) dropped by 19% since coming to market, but some of that may be a symptom of bad timing. Marijuana stocks have been sliding since YOLO's debut and the passively managed ETFMG Alternative Harvest ETF (NYSEARCA:MJ), the largest pot ETF, has dropped 18.5% over the past three months. The Bottom Line: TOKE Has a Big Advantage New ETFs, particularly those entering niches occupied by established competitors, often face difficulties in terms of attracting investors. One way the new funds can thrive, though, is by charging lower fees than their older rivals.That strategy has paid off for at least one cannabis ETF. Cannabis ETF (NYSEARCA:THCX) debuted earlier this month with a 0.70% annual fee, making it, for a moment at least, the cheapest marijuana ETF on the market. THCX has amassed nearly $13 million of assets under management in less than a month of trading. That's pretty good, and it's good news for TOKE.TOKE charges just 0.42% per year, or $42 on a $10,000 investment. That is inexpensive relative to standard actively managed equity funds and really, really cheap compared with the current universe of competing cannabis ETFs. That low fee has the potential to be a significant asset driver for TOKE.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Semiconductor Stocks to Buy for Your Inner Geek * 7 Stocks to Buy That Save You Money * 4 Stocks to Sell Now The post Another Marijuana ETF, Cambria Cannabis, Joins the Party appeared first on InvestorPlace.

  • Benzinga

    You Can Now Trade Options For This Cannabis ETF

    The options are listed on the NYSE Arca Options and NYSE American Options markets. Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more! “As the cannabis sector attracts more institutional investors and professional traders, having options available on THCX is an important step in building the fund's position as the go-to capital markets tool for cannabis exposure," Matt Markiewicz, Managing Director at Innovation Shares, told Benzinga.

  • Marijuana & Blockchain ETFs: Should You Buy?

    Marijuana & Blockchain ETFs: Should You Buy?

    Cannabis and blockchain are high-risk, high-reward areas of the market. Should investors consider these ETFs?

  • Another New Marijuana ETF Takes an Active Approach to Cannabis Investing

    Another New Marijuana ETF Takes an Active Approach to Cannabis Investing

    At the start of this year, there was just one marijuana exchange traded fund (ETF) listed in the U.S. By April, that number had doubled to two and now, with the end of July almost here, the number of marijuana ETFs trading in the U.S. is up to four.So July has been a brisk month in terms of new cannabis ETFs coming to market, as two have accomplished that feat. The newest member of that group is the Amplify Seymour Cannabis ETF (NYSEARCA:CNBS), which debuted on Tuesday, July 23.Like the AdvisorShares Pure Cannabis ETF (NYSEARCA:YOLO), which debuted in April, the Amplify Seymour Cannabis ETF is an actively managed fund. CNBS is run by noted cannabis investor and CNBC personality Tim Seymour.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Oversold Stocks To Buy Right Now "The global legal cannabis industry is still very much in its infancy and presents an attractive growth opportunity for investors looking to capitalize on this emerging frontier," Seymour said in a statement. "Amplify has a track record of offering investors access to disruptive areas of the market via the ETF structure, and the cannabis industry certainly fits this mold." Setting Itself ApartAs more ETFs reflect the same sector, it become more incumbent on the segment's newer funds to differentiate themselves from their more established rivals. This is particularly true of thematic ETFs because investors, rightly or wrongly, may believe certain themes, including cannabis, can only support so many ETFs.For its part, CNBS has some ways of setting itself apart from its more established cannabis ETF rivals. CNBS is somewhat of a cannabis pure play, as 80% of the marijuana stocks within CNBS get " 50% or more of their revenue from the cannabis and hemp ecosystem," according to Amplify.The new marijuana ETF also aims for some diversity at the industry level, which can be somewhat difficult in the still-nascent marijuana business. Six industry groups are represented in CNBS, with 61% of its weight allocated to cannabis cultivators.CNBS' top ten holdings will look familiar to fans of marijuana stocks. Among the names in its top ten are Aurora Cannabis (NYSE:ACB), Canopy Growth (NYSE:CGC) and HEXO Corp (NYSE:HEXO).CNBS would appear to be a mid- to smaller large-cap marijuana ETF, but in reality, it also incorporates smaller marijuana stocks.That is one way CNBS sets itself apart from competing cannabis ETFs; active management can be advantageous when it comes to selecting smaller stocks, particularly in the marijuana space.Smaller marijuana stocks can rise dramatically. So it's interesting to note that more than two-thirds of CNBS' lineup is comprised of small- and micro-cap stocks. The Bottom Line: Fierce CompetitionUndoubtedly, there is fierce competition in the marijuana ETF space, and that competition will only get hotter as more issuers bring marijuana ETFs to market. That is definitely going to happen.As I noted here, fees are battlegrounds for new ETFs to make inroads against their rivals. CNBS charges 0.75% per year, or $75 on a $10,000 investment. That is the same as the ETFMG Alternative Harvest ETF (NYSEARCA:MJ) and 0.1 percentage point more than the aforementioned YOLO, the other active marijuana ETF.In terms of competing with YOLO, CNBS has the potential to make something happen because YOLO has dropped 19% since coming to market.For now, the Cannabis ETF (NYSEARCA:THCX) is the cheapest cannabis ETF on the market with an annual expense ratio of 0.70%.Let's check back in a few months to see how CNBS is stacking up against its rivals mentioned here, especially YOLO, before rendering a decision on this rookie cannabis ETF.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Oversold Stocks To Buy Right Now * 7 Stocks to Buy Upgraded by Wall Street * 7 Marijuana Stocks With Critical Levels to Watch The post Another New Marijuana ETF Takes an Active Approach to Cannabis Investing appeared first on InvestorPlace.